First for Women on MSN12d
La La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'
Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...
Healio9d
‘Strong data’ support ESK-001’s potential as oral treatment for plaque psoriasis
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...
PMLive7d
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme
Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...
Medindia11d
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 ...
BioSpace8d
J&J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
PharmExec11d
Bimzelx Demonstrates Sustained Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...